Lovastatin Tablet
Product Images NDC 63629-1191

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 63629-1191). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl636291191

Lovastatin Tablets, USP 10 mg oral tablets label by Bryant Ranch Prepack. The label shows the strength as 10 mg, with a package size of 1000 tablets. It includes storage instructions, manufacturer information from Carlsbad Technology, Inc., and a requirement for dispensing in a child-resistant container. The label displays the NDC 63629-1191-1 and the BRP Pharmaceuticals logo.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of lovastatin, showing the molecular arrangement of atoms and bonds characteristic of this active ingredient.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' presenting the number of subjects, dosing of coadministered drugs or grapefruit juice, dosing of lovastatin, and AUC ratio comparisons for various drugs including Gemfibrozil, Itraconazole, Grapefruit Juice (high and low dose), Cyclosporine, and Diltiazem.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event over six years of follow-up. Two lines compare Lovastatin and placebo, indicating a 37% risk reduction for the Lovastatin group (p < 0.001). The x-axis represents years of follow-up and the y-axis the proportion of participants without the event.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis.' It lists interacting agents including strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole), HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice. Prescribing recommendations include contraindications and dosage limits when combined with lovastatin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.